Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel

Stroke

Volumn 30, Issue 8, 1999, Pages 1716-1721

  Gorelick, Philip B ^a   Born, Gustav V R ^b   D'Agostino, Ralph B ^c   Hanley Jr , Daniel F ^d   Moye, Lemuel ^e   Pepine, Carl J ^f  

^a Center for Stroke Research   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c BOSTON UNIVERSITY   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Aspirin; Clopidogrel; Decision analysis; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ARTERY DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0032776467     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.8.1716     Document Type: Review

References (47)

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Food and Drug Administration Web site. Drug approvals for November 1997. Available at: http://www.fda.gov.
3. Schafer AI. Antiplatelet therapy. Am J Med. 1996;101:199-209.
4. Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo. Circulation. 1985;72:741-746.
5. Botting RM, Gryglewski RJ, Vane JR. The anti-thrombotic and fibrinolytic actions of aspirin. In: Vane JR, Botting RM, eds. Aspirin and Other Salicylates. New York, NY: Chapman & Hall Medical; 1992: 245-291.
6. Coukell AJ, Markham A. Clopidogrel. Drugs. 1997;54:745-750.
7. Vane JR, Botting RM. The history of aspirin. In: Vane JR, Botting RM, eds. Aspirin and Other Salicylates. New York, NY: Chapman & Hall Medical; 1992:3-16.
8. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953; 75:38-40.
9. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53-59.
10. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330: 1287-1294.
11. Peto R. Aspirin after myocardial infarction. Lancet. 1980;1:1172-1173. Editorial.
12. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R. A randomized controlled trial of acetylsalicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436-440.
13. Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chron Dis. 1976;29:625-642.
14. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2:1313-1315.
15. Breddin K, Loew D, Lechner K, Uberia K, Walte, E. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation. 1980;62:63-72.
16. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA. 1980;243:661-669.
17. Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980;62:449-461.
18. Lewis HD, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doheny JE, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots, H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
19. The SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;338:1345-1349.
20. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry. 1991;54:10441054.
21. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527-539.
22. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992; 340:1421-1425.
23. Patrono C, Collor BS, Dalen JE, Fuster V, Gent M, Harker LA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 1998;114(suppl 5):470S-488S.
24. Dyken ML, Barnett HJM, Easton JD, Fields WS, Fuster V, Hachinski V, Morris JW, Sherman DG. Low-dose aspirin and stroke: "It ain't necessarily so." Stroke. 1992;23:1395-1399.
25. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost. 1996;76:939-943.
26. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1: 1215-1220.
27. Hass WK, Easton JD, Adams HP, Pryse-Phillips W, Molony BA, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501-507.
28. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine: results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990;227: 301-308.
29. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicenter clinical trial. Circulation. 1990;82:17-26.
30. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
31. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997;22:209-215.
32. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1999;280: 1930-1935.
33. Bousser MG, Roberts RS, Gent M. Ticlopidine and clopidogrel in secondary stroke prevention. Cerebrovasc Dis. 1997;7:17-23.
34. Barnett HJM, Meldrum HE. Critique of two putative therapies in stroke prevention using platelet inhibitors. Eur Neurol. 1996;36:253-259.
35. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA. 1998;291:806-810.
36. Noble S, Goa KL. Ticlopidine: a review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischaemia and stroke. Drugs Aging. 1996;8:214-232.
37. Verstraete M. New developments in antiplatelet and antithrombotic therapy. Eur Heart J. 1995;16:16-23.
38. Plavix [executive summary]. Princeton, NJ: Bristol-Myers Squibb Co; 1997.
39. Quirk DM, Barry MJ, Aserkoff B, Podolsky DK. Physician specialty and variation in the cost of treating patients with acute upper gastrointestinal bleeding. Gastroenterology. 1997;113:1443-1448.
40. Medical Economics Company. Drug Topics Red Book. Montvale, NJ: Medical Economics Co Inc; 1997.
41. Medicare Fee Schedule [computer program]. Baltimore, Md: Health Care Financing Administration; 1997.
42. Hospital Cost and Utilization Project, 3. Rockville, Md:, US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1988-1994.
43. Christensen-Szalanski JJJ, Northcraft GB. Patient compliance behavior: the effects of time on patients' values of treatment regimens. Soc Sci Med. 1985;21:263-273.
44. National Council on Patient Information and Education (NCPIE). Prescription Medicine Compliance: A Review of the Baseline of Knowledge. Washington, DC: National Council on Patient Information and Education; 1995.
45. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Research and Manufacturers of America Industry Profile. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1997.
46. Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen K, Boneu B, Cadroy Y. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998;92:1518-1525.
47. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.